THC and Antipsychotics: A Complicated Relationship
Balanced Cannabis Science
50%
An estimated 25-50% of people with schizophrenia use cannabis, yet THC directly opposes every antipsychotic by increasing dopamine in the same pathway these medications suppress.
Psychological Medicine, 2019
Psychological Medicine, 2019
View as imageThe intersection of cannabis and antipsychotic medication is among the most clinically important and pharmacologically complicated drug interactions in psychiatry. Unlike many of the interactions in this series, where the concern is relatively modest -- a mild change in drug levels, an additive side effect, a theoretical risk -- the THC-antipsychotic interaction involves a direct pharmacological opposition between a substance that can trigger psychotic symptoms and a medication designed to treat them.
This is not a theoretical concern. Cannabis use is disproportionately common among people with psychotic disorders. Estimates suggest that 25 to 50 percent of people with schizophrenia use cannabis, compared to approximately 15 percent of the general adult population. The reasons for this overrepresentation are debated, but the clinical consequences are clear: cannabis use in this population is associated with worse outcomes across nearly every measure.
Understanding why requires looking at the pharmacology, the clinical evidence, and the complex relationship between the endocannabinoid system and psychosis.
Key Takeaways
- THC and antipsychotics work directly against each other on dopamine — antipsychotics block dopamine D2 receptors while THC increases dopamine release, creating a fundamental conflict in the brain
- Cannabis use in people with psychotic disorders is linked to more relapses, more hospitalizations, worse symptom control, and poorer medication adherence — even after accounting for other factors
- CBD has shown antipsychotic properties of its own in clinical trials, which creates the paradox that different parts of the same plant have opposing effects on psychosis
- Some antipsychotics like clozapine, olanzapine, and quetiapine are broken down by CYP1A2 and CYP3A4, and smoking cannabis can speed up CYP1A2 — potentially lowering antipsychotic blood levels and making the medication less effective
- The link between cannabis and psychosis goes beyond triggering symptoms in people already at risk — emerging evidence suggests heavy THC use during adolescence may help cause psychotic disorders that would not have developed otherwise
- The CYP1A2 speedup comes from combustion smoke, not THC itself — so switching from smoked cannabis to edibles can paradoxically raise clozapine levels, which means your psychiatrist needs to know before you change delivery methods
The Dopamine Opposition
THC vs Antipsychotics: Pharmacological Opposition
The central pharmacological conflict between THC and antipsychotics occurs at the dopamine D2 receptor. This receptor is the primary target of every antipsychotic medication currently in clinical use and is central to the neurochemical theory of psychosis.
The dopamine hypothesis of schizophrenia holds that positive psychotic symptoms -- hallucinations, delusions, disorganized thinking -- are driven by excessive dopamine signaling in the mesolimbic pathway, particularly at D2 receptors in the striatum and limbic structures. This hypothesis is supported by the fact that every effective antipsychotic blocks D2 receptors, and the clinical potency of antipsychotic drugs correlates directly with their D2 binding affinity.
THC increases dopamine release in the mesolimbic pathway. As described in other articles in this series, THC activates CB1 receptors on GABAergic interneurons in the ventral tegmental area, disinhibiting dopamine neurons and increasing dopamine release in the nucleus accumbens and other limbic structures. This is the same pathway that is hypothesized to be overactive in psychosis.
The result is a direct pharmacological opposition. Antipsychotics reduce mesolimbic dopamine signaling. THC increases it. When a person on an antipsychotic uses cannabis, the THC is partially counteracting the therapeutic mechanism of the medication. The antipsychotic is trying to bring dopamine levels down; the THC is pushing them back up.
The extent to which THC overcomes the antipsychotic blockade depends on the relative doses, the specific antipsychotic's D2 binding affinity, and individual neurobiology. But the direction of the interaction is unambiguous: they work against each other.
Beyond Dopamine: Additional Mechanisms
The THC-psychosis relationship extends beyond dopamine. Research over the past two decades has identified additional mechanisms through which cannabis may promote psychotic symptoms.
Glutamate dysregulation. The endocannabinoid system modulates glutamate release throughout the cortex. THC, through CB1 receptors on glutamatergic terminals, can disrupt the balance between glutamate excitation and GABA inhibition that maintains organized cortical processing. The NMDA receptor hypofunction hypothesis of schizophrenia -- which proposes that reduced glutamate signaling at NMDA receptors contributes to psychotic symptoms -- intersects with THC's effects on glutamate transmission. Some researchers have proposed that THC-induced glutamate dysregulation is an independent mechanism of cannabis-related psychosis, separate from the dopamine story.
Endocannabinoid system dysfunction in psychosis. People with psychotic disorders appear to have altered endocannabinoid system function. CSF levels of anandamide are elevated in first-episode, drug-naive patients with schizophrenia, which may represent a compensatory protective response. Chronic THC use disrupts this endocannabinoid compensatory mechanism by downregulating CB1 receptors and desensitizing the system, potentially removing a natural defense against psychotic symptoms.
Neuroinflammation. Microglia, the brain's resident immune cells, express both cannabinoid receptors and dopamine receptors. Chronic THC exposure alters microglial function in ways that may promote the neuroinflammatory processes increasingly implicated in schizophrenia pathology. Some second-generation antipsychotics have anti-inflammatory properties that may contribute to their therapeutic effects; THC-driven neuroinflammation could counteract this benefit.
Clinical Evidence: Cannabis and Psychosis Outcomes
The clinical literature on cannabis use in people with psychotic disorders is extensive and remarkably consistent in its conclusions.
Relapse rates. A 2019 meta-analysis published in Psychological Medicine found that continued cannabis use after a first episode of psychosis was associated with a significantly higher risk of psychotic relapse compared to discontinuation. The risk was dose-dependent, with heavier use predicting worse outcomes.
Hospitalization. Multiple studies have found that cannabis-using patients with schizophrenia have higher rates of psychiatric hospitalization, longer hospital stays, and more involuntary admissions than non-using patients with the same diagnosis.
Symptom severity. Cannabis use is associated with more severe positive symptoms (hallucinations and delusions) in people with established psychotic disorders. The association with negative symptoms (apathy, social withdrawal, reduced emotional expression) is less consistent, with some studies suggesting that cannabis use may temporarily alleviate negative symptoms, which is one proposed reason for the high prevalence of use in this population.
Treatment adherence. Cannabis use is consistently associated with reduced adherence to antipsychotic medication. Whether this reflects a direct effect (cannabis making the person less motivated to take medication), an indirect effect (cannabis exacerbating the cognitive disorganization that makes medication management difficult), or a shared underlying factor (impulsivity contributing to both cannabis use and non-adherence) is debated. The practical result is the same: cannabis-using patients are less likely to take their antipsychotics as prescribed.
Cognitive function. Schizophrenia is associated with significant cognitive impairments, including deficits in working memory, attention, and executive function. Cannabis use adds further cognitive impairment on top of the illness-related deficits. Studies comparing cannabis-using and non-using patients with schizophrenia have found that users perform worse on neurocognitive testing, though the difference is smaller than might be expected -- possibly because cognitive function is already severely impaired by the illness itself.
The CYP Enzyme Layer
Beyond the receptor-level conflict, pharmacokinetic interactions exist between cannabis and several antipsychotics.
CYP1A2 induction from cannabis smoking. This is one of the most clinically important and underappreciated interactions. Smoking cannabis (like smoking tobacco) produces polycyclic aromatic hydrocarbons from combustion. These hydrocarbons induce CYP1A2, the liver enzyme responsible for metabolizing clozapine and olanzapine. When CYP1A2 is induced, it works faster, breaking down these antipsychotics more rapidly and reducing their blood levels.
Clozapine is particularly sensitive to CYP1A2 induction. It is the only antipsychotic with proven efficacy in treatment-resistant schizophrenia, and its dosing requires careful blood level monitoring. A patient on a stable clozapine dose who begins smoking cannabis may experience a clinically significant drop in clozapine blood levels, leading to psychotic relapse. Conversely, if a patient on clozapine suddenly stops smoking cannabis, the removal of CYP1A2 induction can cause clozapine levels to rise, potentially producing toxicity.
This interaction is driven by the smoke, not the THC. Patients who switch from smoked cannabis to edibles would no longer induce CYP1A2, which could paradoxically cause their clozapine levels to rise. Any change in cannabis route of administration should be communicated to the prescribing psychiatrist.
CYP3A4 interactions. Quetiapine, aripiprazole, and lurasidone are primarily metabolized by CYP3A4. CBD's inhibition of CYP3A4 could slow the metabolism of these antipsychotics, increasing their blood levels and potentially amplifying side effects like sedation, weight gain, and metabolic syndrome.
CYP2D6 interactions. Risperidone and haloperidol are metabolized by CYP2D6. Cannabis has minimal effects on CYP2D6, making these antipsychotics less vulnerable to cannabis-related pharmacokinetic interactions.
The CBD Paradox
One of the most scientifically interesting aspects of the cannabis-psychosis relationship is that while THC is pro-psychotic, CBD appears to be antipsychotic. The two most abundant cannabinoids in the cannabis plant have opposing effects on psychotic symptoms.
A 2018 randomized controlled trial published in the American Journal of Psychiatry by McGuire and colleagues found that CBD (1000 mg daily) added to antipsychotic medication produced significant improvement in positive psychotic symptoms compared to placebo plus antipsychotic. CBD was well tolerated and produced no significant side effects beyond those of the baseline medication.
CBD's antipsychotic mechanism does not appear to involve D2 receptor blockade, which is the mechanism of conventional antipsychotics. Instead, CBD may work through modulation of anandamide signaling. CBD inhibits fatty acid amide hydrolase (FAAH), the enzyme that breaks down anandamide, increasing endocannabinoid levels. The elevated anandamide associated with first-episode psychosis appears to be protective, and CBD may enhance this protective mechanism.
This creates a paradox: the cannabis plant contains both a substance that worsens psychosis (THC) and a substance that may treat it (CBD). The ratio between these two substances matters enormously. High-THC, low-CBD cannabis strains (which dominate modern legal and illegal markets) present the worst risk profile for psychosis-vulnerable individuals. Higher-CBD strains or pure CBD products may have neutral or even beneficial effects.
However, this nuance has not translated into clinical guidance to use CBD-rich cannabis as a psychosis treatment. The McGuire trial used pharmaceutical-grade CBD, not commercial cannabis products, and the dose (1000 mg daily) far exceeds what most cannabis products deliver. Advising patients with psychotic disorders to use cannabis in any form remains outside current clinical practice guidelines.
Cannabis and Psychosis Onset: The Developmental Question
The most consequential and most debated aspect of the cannabis-psychosis relationship is whether cannabis causes psychosis or merely triggers it in people who would have developed it regardless.
The evidence now suggests that both may be true, but the causal contribution appears to be dose-dependent and developmentally specific.
A landmark 2019 study published in The Lancet Psychiatry analyzed data from 11 sites across Europe and found that daily use of high-potency cannabis (more than 10 percent THC) was associated with a five-fold increase in the risk of a first episode of psychosis compared to never-use. The association was strongest in Amsterdam and London, where high-potency cannabis dominated the market. The authors estimated that if high-potency cannabis were not available, roughly 12 percent of first-episode psychosis cases across the study sites would have been prevented.
Adolescent exposure is particularly concerning. The brain undergoes extensive development during adolescence, including maturation of the endocannabinoid system, refinement of dopaminergic pathways, and synaptic pruning in the prefrontal cortex. Heavy THC exposure during this window of vulnerability may produce lasting changes in these systems that increase psychosis risk. Genetic factors, particularly variation in the COMT gene that affects dopamine metabolism, appear to moderate this vulnerability, making some adolescents substantially more susceptible to cannabis-induced psychotic outcomes than others.
Practical Implications
If you take an antipsychotic, your prescriber needs to know about cannabis use. This is not a suggestion for the sake of completeness -- it is a clinical imperative. Cannabis directly opposes the mechanism of your medication and can alter its blood levels through CYP enzyme interactions. Your treatment cannot be properly managed without this information.
If you smoke cannabis and take clozapine or olanzapine, this is urgent. The CYP1A2 induction from smoking can produce clinically dangerous changes in antipsychotic blood levels. Your psychiatrist needs to know about the quantity and route of your cannabis use to dose your medication correctly.
The type of cannabis matters. High-THC, low-CBD cannabis poses the greatest risk for psychosis exacerbation. If cannabis use is going to occur, lower-THC products with meaningful CBD content represent a less risky option, though this has not been validated in clinical studies as a harm reduction strategy.
Cannabis cessation improves outcomes. The evidence is consistent: people with psychotic disorders who reduce or discontinue cannabis use experience fewer relapses, better symptom control, and improved cognitive function. This does not mean cessation is easy -- cannabis use in this population is often deeply entrenched and serves important subjective functions -- but it means the effort has a meaningful payoff.
If you have a family history of psychosis, the risk calculation changes. First-degree relatives of people with schizophrenia are already at elevated genetic risk. Heavy cannabis use in this population represents a modifiable risk factor for a devastating illness. This information is particularly relevant for adolescents and young adults with family histories of psychosis.
The THC-antipsychotic interaction is not just a drug interaction -- it is a collision between a disease process and a substance that exacerbates it, complicated by pharmacokinetic layers and a dose-dependent relationship that begins with adolescent exposure and extends through the lifespan. Of all the interactions in this series, this one most clearly warrants a conversation with a healthcare provider before any decisions are made.
The Bottom Line
Evidence review of THC-antipsychotic interactions covering dopamine opposition, additional psychosis mechanisms, clinical outcomes, CYP enzymes, CBD paradox, and developmental psychosis risk. Dopamine opposition: antipsychotics block D2 receptors (potency correlates with D2 affinity); THC increases mesolimbic dopamine via CB1 disinhibition of VTA GABAergic interneurons; direct pharmacological conflict. Additional mechanisms: glutamate dysregulation (CB1 on glutamatergic terminals disrupts NMDA signaling); elevated CSF anandamide in first-episode psychosis = protective compensatory response disrupted by chronic THC; neuroinflammation via altered microglial function. Clinical outcomes: Psychological Medicine 2019 meta-analysis — continued cannabis use after first episode = higher relapse risk (dose-dependent); more hospitalizations, worse positive symptoms, reduced medication adherence, worse neurocognitive testing. CYP interactions: cannabis smoke induces CYP1A2 → lowers clozapine/olanzapine levels (clozapine most sensitive); CBD inhibits CYP3A4 → may increase quetiapine/aripiprazole/lurasidone; CYP2D6 (risperidone/haloperidol) = minimal cannabis effect. CBD paradox: McGuire 2018 American Journal of Psychiatry RCT — CBD 1000mg/day + antipsychotic improved positive symptoms vs placebo; mechanism = FAAH inhibition increasing anandamide; high-THC low-CBD strains = worst risk profile. Developmental risk: Lancet Psychiatry 2019 — daily high-potency cannabis = 5x first-episode psychosis risk; 12% of cases preventable; COMT gene moderates vulnerability.
Frequently Asked Questions
Sources & References
- 1RTHC-08362·Javed, Mohammad Saad et al. (2026). “About One-Third of People With Cannabis-Induced Psychosis Later Develop Schizophrenia.” BMC psychiatry.Study breakdown →PubMed →↩
- 2RTHC-00141·Iversen, Leslie (2003). “Cannabis and the Brain: A Comprehensive Review Published in Brain.” Brain : a journal of neurology.Study breakdown →PubMed →↩
- 3RTHC-00228·Henquet, Cécile et al. (2006). “Cannabis Use Nearly Tripled the Risk of Developing Manic Symptoms Over Three Years.” Journal of affective disorders.Study breakdown →PubMed →↩
- 4RTHC-07434·Rajput, Jaisingh et al. (2025). “Cannabis and Schizophrenia: Risk Factor, Treatment, or Both?.” Cureus.Study breakdown →PubMed →↩
- 5RTHC-02255·Reid, Sam et al. (2019). “Cannabis use in psychosis patients is linked to antipsychotic treatment failure.” Psychiatry research.Study breakdown →PubMed →↩
- 6RTHC-00345·Aragona, Massimiliano et al. (2009). “Sativex Did Not Cause Psychiatric Problems or Cognitive Decline in Cannabis-Naive MS Patients.” Clinical neuropharmacology.Study breakdown →PubMed →↩
- 7RTHC-00328·Roser, Patrik et al. (2008). “THC Reduced Brain Attention Responses, and CBD Didn't Reverse It in This Study.” European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology.Study breakdown →PubMed →↩
- 8RTHC-00279·Juckel, Georg et al. (2007). “Cannabis Extract With CBD Boosted Auditory Brain Responses While Pure THC Alone Did Not.” Schizophrenia research.Study breakdown →PubMed →↩
Research Behind This Article
Showing the 8 most relevant studies from our research database.
Prevalence of schizophrenia spectrum and bipolar disorder among patients with cannabis induced psychosis: a systematic review and meta-analysis.
Javed, Mohammad Saad · 2026
Pooling data from 13 studies with a total of 7,515 patients diagnosed with cannabis-induced psychosis, this meta-analysis calculated the rates at which these individuals later received diagnoses of schizophrenia spectrum disorder or bipolar disorder. The conversion rates were substantial.
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
McGuire, Philip · 2018
In 88 patients with schizophrenia already on antipsychotics, adding 1000 mg/day CBD for 6 weeks significantly reduced positive psychotic symptoms (PANSS positive difference: -1.4, p=0.019) and increased clinician-rated improvement (OR 3.65, p=0.017) versus placebo.
Cannabis use and expression of mania in the general population.
Henquet, Cécile · 2006
Researchers followed 4,815 individuals aged 18-64 years in a longitudinal population-based study with assessments at baseline, one year, and three years.
Cannabis and the brain.
Iversen, Leslie · 2003
All known central effects of THC were mediated through CB1 receptors, with particularly high expression on GABAergic interneurons in the hippocampus, amygdala, and cerebral cortex.
The Relationship Between Cannabis Use and Schizophrenia As a Risk Factor or For Its Therapeutic Potential: A Systematic Review of Evidence.
Rajput, Jaisingh · 2025
The cannabis-schizophrenia relationship is one of the most polarized debates in psychiatric research.
Antipsychotic treatment failure in patients with psychosis and co-morbid cannabis use: A systematic review.
Reid, Sam · 2019
Seven studies met inclusion criteria.
Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study.
Aragona, Massimiliano · 2009
Seventeen cannabis-naive MS patients were randomized in a double-blind crossover trial to receive Sativex or placebo for 3-week periods, with comprehensive psychological and cognitive assessments. No significant differences were found between the Sativex and placebo phases on any measured psychological or cognitive variable.
Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers.
Roser, Patrik · 2008
In a double-blind crossover study, 20 healthy volunteers received pure THC, a standardized cannabis extract containing THC and CBD, or placebo on separate occasions. As expected, pure THC significantly reduced P300 amplitude at frontal, central, and parietal electrodes.